Top

Published in:

01-02-2010 | Review

Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain

Authors: Cimona V. Hinton, Shalom Avraham, Hava Karsenty Avraham

Published in: Clinical & Experimental Metastasis | Issue 2/2010

Abstract

Breast cancer is the most common malignancy and second leading cause of cancer death in women. Ninety percent of mortality in breast cancer is often associated with metastatic progression or relapse in patients. Critical stages in the development of aggressive breast cancer include the growth of primary tumors and their ability to spread to foreign organs and form metastases, as well as the establishment of an independent blood supply within the new tumors. Hence, it is imperative to characterize the key molecules that regulate the metastasis of human breast cancer cells. The expression of CXCR4/CXCL12 in breast tumors has been correlated with a poor prognosis, increased metastasis, resistance to conventional therapeutic agents and a poor outcome in the pathogenesis of breast cancer. However, effective anti-CXCR4 therapy remains a challenge. Here, we will review the putative involvement of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Characterization of signaling events important for breast cancer cell growth and their metastasis to the brain should provide insights into breast cancer therapies and improved, successful treatments for breast cancer.

Internet publication www.womancando.org

Karnoub AE, Weinberg RA (2006–2007) Chemokine networks and breast cancer metastasis. Breast Dis 26:75–85

Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D et al (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104:6740–6745. doi:10.1073/pnas.0701138104 CrossRefPubMed

Dupont VN, Gentien D, Oberkampf M, De Rycke Y, Blin N (2007) A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. Int J Cancer 121:1036–1046. doi:10.1002/ijc.22775 CrossRefPubMed

Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C et al (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446:765–770. doi:10.1038/nature05760 CrossRefPubMed

Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ et al (2007) In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci USA 104:6696–6701. doi:10.1073/pnas.0701145104 CrossRefPubMed

Chang EL, Lo S (2003) Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 8:398–410. doi:10.1634/theoncologist.8-5-398 CrossRefPubMed

Boogerd W (1996) Central nervous system metastasis in breast cancer. Radiother Oncol 40:5–22. doi:10.1016/0167-8140(96)01766-5 CrossRefPubMed

Boogerd W, Vos VW, Hart AA, Baris G (1993) Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 15:165–174. doi:10.1007/BF01053937 CrossRefPubMed

10.

Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward JL (1981) Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17:449–453PubMed

11.

Sparrow GE, Rubens RD (1981) Brain metastases from breast cancer: clinical course, prognosis and influence of treatment. Clin Oncol 7:291–301PubMed

12.

Nicolson GL, Menter DG, Herrmann J, Cavanaugh P, Jia L, Hamada J et al (1994) Tumor metastasis to brain: role of endothelial cells, neurotrophins, and paracrine growth factors. Crit Rev Oncog 5:451–471PubMed

13.

Wiseman BS, Werb Z (2002) Stromal effects on mammary gland development and breast cancer. Science 296:1046–1049. doi:10.1126/science.1067431 CrossRefPubMed

14.

Hesselgesser J, Halks-Miller M, DelVecchio V, Peiper SC, Hoxie J, Kolson DL et al (1997) CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr Biol 7:112–121. doi:10.1016/S0960-9822(06)00055-8 CrossRefPubMed

15.

Ohtani Y, Minami M, Kawaguchi N, Nishiyori A, Yamamoto J, Takami S et al (1998) Expression of stromal cell-derived factor-1 and CXCR4 chemokine receptor mRNAs in cultured rat glial and neuronal cells. Neurosci Lett 249:163–166. doi:10.1016/S0304-3940(98)00425-X CrossRefPubMed

16.

Tanabe S, Heesen M, Yoshizawa I, Berman MA, Luo Y, Bleul CC et al (1997) Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol (Baltimore, MD.: 1950) 159:905–911

17.

Volin MV, Joseph L, Shockley MS, Davies PF (1998) Chemokine receptor CXCR4 expression in endothelium. Biochem Biophys Res Commun 242:46–53. doi:10.1006/bbrc.1997.7890 CrossRefPubMed

18.

Feil C, Augustin HG (1998) Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. Biochem Biophys Res Commun 247:38–45. doi:10.1006/bbrc.1998.8499 CrossRefPubMed

19.

Dollé L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, Hondermarck H (2003) Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 22:5592–5601. doi:10.1038/sj.onc.1206805 CrossRefPubMed

20.

Dollé L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V, Hondermarck H (2004) Nerve growth factor receptors and signaling in breast cancer. Curr Cancer Drug Targets 4:463–470. doi:10.2174/1568009043332853 CrossRefPubMed

21.

Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R et al (2008) Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res 68:346–351. doi:10.1158/0008-5472.CAN-07-1183 CrossRefPubMed

22.

Prince JM, Klinowska TC, Marshman E, Lowe ET, Mayer U, Miner J et al (2002) Cell-matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Dev Dyn 223:497–516. doi:10.1002/dvdy.10070 CrossRefPubMed

23.

El Yazidi-Belkoura I, Adriaenssens E, Dollé L, Descamps S, Hondermarck H (2003) Tumor necrosis factor receptor-associated death domain protein is involved in the neurotrophin receptor-mediated antiapoptotic activity of nerve growth factor in breast cancer cells. J Biol Chem 278:16952–16956. doi:10.1074/jbc.M300631200 CrossRefPubMed

24.

Dollé L, Oliveira MJ, Bruyneel E, Hondermarck H, Bracke M (2005) Nerve growth factor mediates its pro-invasive effect in parallel with the release of a soluble E-cadherin fragment from breast cancer MCF-7/AZ cells. J Dairy Res 72:20–26. doi:10.1017/S0022029905001160 CrossRefPubMed

25.

Dollé JP, Rezvan A, Allen FD, Lazarovici P, Lelkes PI (2005) Nerve growth factor-induced migration of endothelial cells. J Pharmacol Exp Ther 315:1220–1227. doi:10.1124/jpet.105.093252 CrossRefPubMed

26.

Lai R, Dang C, Malkin M, Abrey L (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810–816. doi:10.1002/cncr.20418 CrossRefPubMed

27.

Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913–920PubMed

28.

Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977. doi:10.1002/cncr.11436 CrossRefPubMed

29.

Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM et al (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67:4190–4198. doi:10.1158/0008-5472.CAN-06-3316 CrossRefPubMed

30.

Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, International Breast Cancer Study Group (IBCSG) et al (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935–944. doi:10.1093/annonc/mdl064 CrossRefPubMed

31.

Cheng X, Hung MC (2007) Breast cancer brain metastases. Cancer Metastasis Rev 26:635–643. doi:10.1007/s10555-007-9083-x CrossRefPubMed

32.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. doi:10.1056/NEJM200103153441101 CrossRefPubMed

33.

Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643PubMed

34.

Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J et al (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14:1072–1077. doi:10.1093/annonc/mdg300 CrossRefPubMed

35.

Fuchs IB, Loebbecke M, Buhler H, Stoltenburg-Didinger G, Heine B, Lichtenegger W et al (2002) HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol 20:4130–4133. doi:10.1200/JCO.2002.04.016 CrossRefPubMed

36.

Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH et al (2003) Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 9:5514–5520PubMed

37.

Montemurro F, Valabrega G, Aglietta M (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 7:257–268. doi:10.1517/14712598.7.2.257 CrossRefPubMed

38.

Dewji MR (2004) Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn? J Chemother (Florence, Italy) 16(Suppl 4):44–48

39.

Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617. doi:10.1200/JCO.2004.01.175 CrossRefPubMed

40.

Olesen SP (1986) Rapid increase in blood-brain barrier permeability during severe hypoxia and metabolic inhibition. Brain Res 368:24–29. doi:10.1016/0006-8993(86)91038-3 CrossRefPubMed

41.

Tanno H, Nockels RP, Pitts LH, Noble LJ (1992) Breakdown of the blood-brain barrier after fluid percussion brain injury in the rat: part 2: effect of hypoxia on permeability to plasma proteins. J Neurotrauma 9:335–347CrossRefPubMed

42.

Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25. doi:10.1210/er.18.1.4 CrossRefPubMed

43.

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22PubMed

44.

Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844CrossRefPubMed

45.

Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60:5117–5124PubMed

46.

Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629–5632PubMed

47.

Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF et al (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86–91. doi:10.1016/0046-8177(95)90119-1 CrossRefPubMed

48.

Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC et al (1993) Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153–159. doi:10.1172/JCI116165 CrossRefPubMed

49.

Lee TH, Avraham HK, Jiang S, Avraham S (2003) Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem 278:5277–5284. doi:10.1074/jbc.M210063200 CrossRefPubMed

50.

Kim LS, Huang S, Lu W, Lev DC, Price JE (2004) Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21:107–118. doi:10.1023/B:CLIN.0000024761.00373.55 CrossRefPubMed

51.

Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S et al (2000) Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54:1670–1676PubMed

52.

Rollins BJ (1997) Chemokines. Blood 90:909–928PubMed

53.

Premack BA, Schall TJ (1996) Chemokine receptors: gateways to inflammation and infection. Nat Med 2:1174–1178. doi:10.1038/nm1196-1174 CrossRefPubMed

54.

Bokoch GM (1995) Chemoattractant signaling and leukocyte activation. Blood 86:1649–1660PubMed

55.

Gerard C, Gerard NP (1994) The pro-inflammatory seven-transmembrane segment receptors of the leukocyte. Curr Opin Immunol 6:140–145. doi:10.1016/0952-7915(94)90045-0 CrossRefPubMed

56.

Taub DD, Oppenheim JJ (1994) Chemokines, inflammation and the immune system. Ther Immunol 1:229–246PubMed

57.

Luster AD (1998) Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338:436–445. doi:10.1056/NEJM199802123380706 CrossRefPubMed

58.

Loetscher P, Moser B, Baggiolini M (2000) Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol 74:127–180. doi:10.1016/S0065-2776(08)60910-4 CrossRefPubMed

59.

Miller MD, Krangel MS (1992) Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 12:17–46PubMed

60.

Appleton I (1994) Wound repair: the role of cytokines and vasoactive mediators. J R Soc Med 87:500–502PubMed

61.

Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM (1998) Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem 273:4282–4287. doi:10.1074/jbc.273.7.4282 CrossRefPubMed

62.

Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127. doi:10.1016/S1074-7613(00)80165-X CrossRefPubMed

63.

Lau EK, Allen S, Hsu AR, Handel TM (2004) Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins. Adv Protein Chem 68:351–391. doi:10.1016/S0065-3233(04)68010-7 CrossRefPubMed

64.

Negus RP (1996) The chemokines: cytokines that direct leukocyte migration. J R Soc Med 89:312–314PubMed

65.

Clore GM, Gronenborn AM (1995) Three-dimensional structures of alpha and beta chemokines. FASEB J 9:57–62PubMed

66.

Baggiolini M, Dewald B, Moser B (1997) Human chemokines: an update. Annu Rev Immunol 15:675–705. doi:10.1146/annurev.immunol.15.1.675 CrossRefPubMed

67.

Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550. doi:10.1038/nrc1388 CrossRefPubMed

68.

Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T et al (1995) Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 28:495–500. doi:10.1006/geno.1995.1180 CrossRefPubMed

69.

Hamada T, Tashiro K, Tada H, Inazawa J, Shirozu M, Shibahara K et al (1996) Isolation and characterization of a novel secretory protein, stromal cell-derived factor-2 (SDF-2) using the signal sequence trap method. Gene 176:211–214. doi:10.1016/0378-1119(96)00251-X CrossRefPubMed

70.

Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J et al (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382:829–833. doi:10.1038/382829a0 CrossRefPubMed

71.

Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872–877. doi:10.1126/science.272.5263.872 CrossRefPubMed

72.

Federsppiel B, Melhado IG, Duncan AM, Delaney A, Schappert K, Clark-Lewis I et al (1993) Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen. Genomics 16:707–712. doi:10.1006/geno.1993.1251 CrossRefPubMed

73.

Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392:565–568. doi:10.1038/33340 CrossRefPubMed

74.

Nagasawa T, Kikutani H, Kishimoto T (1994) Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 91:2305–2309. doi:10.1073/pnas.91.6.2305 CrossRefPubMed

75.

Nomura H, Nielsen BW, Matsushima K (1993) Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int Immunol 5:1239–1249. doi:10.1093/intimm/5.10.1239 CrossRefPubMed

76.

Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184:1101–1109. doi:10.1084/jem.184.3.1101 CrossRefPubMed

77.

Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T et al (1998) Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 95:9448–9453. doi:10.1073/pnas.95.16.9448 CrossRefPubMed

78.

Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393:595–599. doi:10.1038/31269 CrossRefPubMed

79.

Lataillade JJ, Clay D, Bourin P, Hérodin F, Dupuy C, Jasmin C et al (2002) Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism. Blood 99:1117–1129. doi:10.1182/blood.V99.4.1117 CrossRefPubMed

80.

Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56. doi:10.1038/35065016 CrossRefPubMed

81.

Kato M, Kitayama J, Kazama S, Nagawa H (2003) Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5:R144–R150. doi:10.1186/bcr627 CrossRefPubMed

82.

Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335–348. doi:10.1016/j.cell.2005.02.034 CrossRefPubMed

83.

Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H et al (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6:17–32. doi:10.1016/j.ccr.2004.06.010 CrossRefPubMed

84.

Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K et al (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100:13513–13518. doi:10.1073/pnas.2235846100 CrossRefPubMed

85.

Zhou Y, Larsen PH, Hao C, Yong VW (2002) CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 277:49481–49487. doi:10.1074/jbc.M206222200 CrossRefPubMed

86.

Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP et al (2001) A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol (Baltimore, MD.: 1950) 167:4747–4757

87.

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549. doi:10.1016/S1535-6108(03)00132-6 CrossRefPubMed

88.

Chen Y, Stamatoyannopoulos G, Song CZ (2003) Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 63:4801–4804PubMed

89.

Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD et al (2003) NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278:21631–21638. doi:10.1074/jbc.M300609200 CrossRefPubMed

90.

Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L (eds) (2001) SEER cancer statistics review. Natl Cancer Inst Bethesda, MD

91.

Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N (2003) NT140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 550:79–83. doi:10.1016/S0014-5793(03)00824-X CrossRefPubMed

92.

Fischer OM, Hart S, Gschwind A, Ullrich A (2003) EGFR signal transactivation in cancer cells. Biochem Soc Trans 31:1203–1208CrossRefPubMed

93.

Luttrell DK, Luttrell LM (2004) Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene 23:7969–7978. doi:10.1038/sj.onc.1208162 CrossRefPubMed

94.

Porcile C, Bajetto A, Barbero S, Pirani P, Schettini G (2004) CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann N Y Acad Sci 1030:162–169. doi:10.1196/annals.1329.021 CrossRefPubMed

95.

Venkatakrishnan G, Salgia R, Groopman JE (2000) Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 275(10):6868–6875. doi:10.1074/jbc.275.10.6868 CrossRefPubMed

96.

Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M et al (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6:459–469. doi:10.1016/j.ccr.2004.09.027 CrossRefPubMed

97.

Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S et al (2005) CXCL-12/stromal cell-derived factor-1 transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65:6493–6497. doi:10.1158/0008-5472.CAN-04-1303 CrossRefPubMed

98.

Lin J, Freeman MR (2003) Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells. Prostate 54:1–7. doi:10.1002/pros.10160 CrossRefPubMed

99.

Gschwind A, Prenzel N, Ullrich A (2002) Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 62:6329–6336PubMed

100.

Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML (2008) CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 6:446–457. doi:10.1158/1541-7786.MCR-07-0117 CrossRefPubMed

101.

Kishimoto H, Wang Z, Bhat-Nakshatri P, Chang D, Clarke R, Nakshatri H (2005) The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. Carcinogenesis 26:1706–1715. doi:10.1093/carcin/bgi137 CrossRefPubMed

Title: Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain
Authors: Cimona V. Hinton
Shalom Avraham
Hava Karsenty Avraham
Publication date: 01-02-2010
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 2/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9210-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Protracted disseminated skeletal metastases from angiosarcoma of the spleen

FAK is involved in invasion and metastasis of hepatocellular carcinoma

Id2 deficiency promotes metastasis in a mouse model of ocular cancer

Dietary fat alters pulmonary metastasis of mammary cancers through cancer autonomous and non-autonomous changes in gene expression

A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer